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The characteristics of dyspnoea in idiopathic pulmonary fibrosis (IPF) during a 6-min walk
test are not clear. This study was designed to evaluate dyspnoea and desaturation during
the 6-min walk test in IPF in comparison with that in chronic obstructive pulmonary disease
(COPD), which is one of the most studied chronic lung diseases.
The 41 consecutive patients with IPF included in this study were assessed by a 6-min walk
test and concurrent measures of disease severity. Forty-one age-matched and resting PaO2
value-matched COPD patients who had undertaken the test during the same period were
selected as the control.
Only O2 saturation at the end of the test was an independent predictor of dyspnoea in IPF
(r2 ¼ 0.27, P ¼ 0.0005), whereas forced expiratory volume in 1 s (FEV1) was the only
predictor in COPD (r2 ¼ 0.16, P ¼ 0.0096). Desaturation was significantly more severe in
IPF (83.679.1% in IPF versus 88.075.9% in COPD, Po0.001). In contrast, dyspnoea
assessed with the Borg scale was significantly more severe in COPD (3.672.1 in IPF versus
4.671.9 in COPD, Po0.05).
O2 saturation is an independent predictor of dyspnoea at the end of a 6-min walk test in
IPF. In comparison with COPD, desaturation is more severe, although dyspnoea is milder.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Exertional dyspnoea is one of the main symptoms in patients
with idiopathic pulmonary fibrosis (IPF). As the disease
progresses, the daily activity of patients gradually declines
because of the dyspnoea.1,2 Thus, managing dyspnoea in
daily living seems important to improve the quality of life in
patients with IPF. However, there has been no definite
ARTICLE IN PRESS
O. Nishiyama et al.834treatment proven to be effective for improving dyspnoea in
IPF.3,4 Moreover, the mechanisms underlying exertional
dyspnoea in these patients have not been sufficiently
elucidated.
In contrast, there are many reports on dyspnoea in
chronic obstructive pulmonary disease (COPD), and exer-
tional dyspnoea is now recognized as one of the key factors
in the management of patients with COPD.5,6 Reducing
exertional dyspnoea is usually viewed as one of primary
outcomes in either pharmacologic or non-pharmacologic
interventions for COPD. Inhalation with bronchodilators and
pulmonary rehabilitation programs have been demonstrated
to improve dyspnoea and the health-related quality of
life.5,6 Furthermore, dyspnoea in daily life has been proven
to be a significant prognostic factor in COPD.7,8
Exercise capacity is another important outcome in
managing COPD. Because of its simplicity, the 6-min walk
test is often adopted,8 and therefore exertional dyspnoea
accompanying the test is frequently evaluated. Since the 6-
min walk test is recognized as a functional exercise test,9
assessing dyspnoea during this exercise test comes extre-
mely close to evaluating dyspnoea in daily activities.
Recently, exercise capacity has also been recognized as
important in IPF as well because of its prognostic signifi-
cance.10–12 The 6-min walk test has been frequently adopted
to evaluate exercise capacity, and also is reported to be a
reproducible evaluation method in IPF.13 However, the
characteristic of dyspnoea during a 6-min walk test, which
seems to be the most recommended method for evaluating
exercise capacity, is not clear in IPF. Therefore, in this study,
we evaluated dyspnoea and desaturation during the 6-min
walk test in patients with IPF and compared them to those in
COPD, one of the most studied chronic lung diseases, to
elucidate any differences.Methods
Study population
Forty-one consecutive patients with IPF, who had underwent
a 6-min walk test as is the general practice in Tosei General
Hospital were included in this study. All patients were
diagnosed with IPF by the diagnostic criteria in the American
Thoracic Society/European Respiratory Society (ATS/ERS)
consensus statement.2 Surgical lung biopsies were per-
formed in 21 patients, and the pathological diagnosis of
usual interstitial pneumonia was also based on the consensus
statement.2 Patients were excluded if they had any of the
following: obvious COPD, active coronary artery disease, or
other severe comorbid illness. All patients enrolled in the
study were newly diagnosed with IPF and had not yet
received any treatment, such as corticosteroids or cytotoxic
agents. Patients who could not perform exercise testing
were excluded. Patients who were taking long-term oxygen
therapy were also excluded. Forty-one age-matched and
resting PaO2 value-matched COPD patients who had under-
taken the 6-min walk test in the same hospital during the
same period were selected as controls. All these patients
were diagnosed with COPD by the ATS guideline,14 and they
fulfilled the following criteria: cigarette smoking420 pack-
years, forced expiratory volume in 1 s (FEV1)p70% pre-dicted, no history suggestive of asthma. Patients taking
long-term oxygen therapy were not included.
This report is based on a retrospective analysis of
clinically indicated studies of patients with IPF performed
in our hospital. The patients with IPF in this study have been
the subjects in previous articles on various aspects of
IPF.15,16Pulmonary function tests
All patients underwent spirometry (CHESTAC-55V; Chest,
Tokyo, Japan), according to the method described in the
American Thoracic Society 1994 update.17 Total lung
capacity (TLC) was obtained using helium dilution, and
single-breath diffusing capacity (DLco) was also measured
(CHESTAC-55V; Chest, Tokyo, Japan). The values for vital
capacity (VC), TLC, and DLco were related to predicted
values.18Six-min walk test
Functional exercise capacity was measured by a 6-min
walking test, according to the ATS statement.9 Briefly, all
patients were tested under standardized conditions by
trained technicians. Baseline blood pressure, heart rate,
and O2 saturation were measured. Patients were instructed
to walk as far as possible for 6min. The distance the patients
could walk was recorded. O2 saturation was also measured
by pulse oximetry at rest for 5min prior to the test and
immediately after it. All patients underwent the tests twice
to minimize the training effects. Patients were asked to rate
their dyspnoea at the end of the test, using the modified
Borg scale by selecting a number from 0 to 10, with 0 being
no appreciable dyspnoea and 10 being maximal sustainable
dyspnoea.19Statistics
The unpaired t-test was used to compare variables between
the two groups. Pearson’s correlation coefficients (r) were
determined to examine the degree of correlation among
resting lung functional variables, a 6-min walk distance, and
dyspnoea at the end of the test. For the variables
significantly related to the 6-min walk distance and
dyspnoea at the end of the test, a stepwise multiple
regression analysis was performed to reveal the most
relevant variable. Variables used in the model included
pulmonary function, DLco, resting PaO2, and O2 saturation at
the end of the exercise test. A P-value of less than 0.05 was
considered significant. All values are presented as mean
7SD.Results
Baseline characteristics of subjects
As shown in Table 1, decreases in VC and TLC in patients with
IPF were mild, showing that a restrictive defect was
relatively mild. Although moderate reduction in DLco was
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Table 1 Characteristics of patients with IPF and COPD.
Variables IPF COPD P-value
Gender (M/F) 35/6 39/2 NS
Age (yr) 6479 66710 NS
VC (L) 2.570.7 2.970.8 0.02
VC (% pred) 76.6716.8 88.4717.8 0.02
TLC (L) 3.971.0 5.571.1 o0.0001
TLC (% pred) 77.7718.3 107.9714.3 o0.0001
FEV1 (L) 2.070.5 1.170.5 o0.0001
FEV1 (% pred) 85.5720.8 45.8716.1 o0.0001
RV/TLC (%) 39.6731.0 47.478.9 NS
RV/TLC (% pred) 111.9726.0 154.7728.7 o0.0001
IC (L) 1.670.5 1.870.5 NS
DLco (mL/min/mmHg) 10.673.9 13.974.3 0.0006
DLco (% pred) 58.9720.4 91.1729.6 o0.0001
DLco/VA (% pred) 75.9723.3 70.8724.1 NS
PaO2 (mmHg) 82.3714.2 80.6710.9 NS
PaCO2 (mmHg) 36.875.9 39.376.3 NS
Data presented as n, mean7SD.
Table 2 Correlation between 6-min walk distance and
various physiologic parameters.
Variables Six-min walk distance (m)
IPF COPD
VC 0.55y 0.58*
TLC 0.33z 0.23
FEV1 0.54
y 0.70*
RV/TLC 0.06 0.67*
IC 0.42z 0.45z
DLco 0.51y 0.20
PaO2 at rest 0.32
z 0.22
O2 saturation at end of
6-min walk test
0.25 0.11
Data presented as r values with single regression analysis by
Pearson’s correlation coefficients. *Po0.0001; yPo0.001;
zPo0.01; zPo0.05.
Dyspnoea at 6-min walk test in IPF 835observed, the resting PaO2 value was not much reduced in
the IPF group.
Compared to patients with COPD, there were no
significant differences in the male/female ratio between
the two groups. Age and the resting PaO2 value were
comparable because they were matched in the two groups,
and no significant difference was observed in the PaCO2
value in either group. VC, TLC, and residual volume (RV)/
TLC ratio were lower in the IPF group, and FEV1 was worse in
the COPD group, showing a restrictive defect in IPF and an
obstructive disorder in COPD.
Correlates of 6-min walk distance
In the single correlation analysis, the 6-min walk distance
was significantly related to VC, TLC, FEV1, inspiratory
capacity (IC), DLco, and PaO2 at rest in IPF. However,
significant correlates in COPD were VC, FEV1, RV/TLC, and IC
(Table 2).
In stepwise multiple regression analysis, VC, TLC, and
DLco were independent predictors of the 6-min walk
distance in IPF (r2 ¼ 0.47, Po0.0001). In contrast, FEV1
and RV/TLC (r2 ¼ 0.51, Po0.0001) were significant con-
tributing variables in COPD (Table 3).
Correlates of dyspnoea scale at end of walk test
In single regression analysis, the Borg scale at the end of the
6-min walk test was significantly related to VC, FEV1, resting
PaO2, and O2 saturation at the end of the test. In COPD,
significant correlates to dyspnoea scale were FEV1 and RV/
TLC (Table 4).
In stepwise multiple regression analysis, only O2 satura-
tion at the end of the exercise test was an independent
predictor of dyspnoea at the end of the test in IPF
(r2 ¼ 0.27, P ¼ 0.0005), whereas only FEV1 was an indepen-
dent predictor in COPD (r2 ¼ 0.16, P ¼ 0.0096) (Table 5).Comparison of desaturation and dyspnoea at end of
walk test
The 6-min walk distance was comparable in both the IPF and
COPD groups. Although desaturation was observed at the
end of the walk test in both groups, the level was
significantly lower (more severe) in IPF. In contrast, the
Borg scale at the end of the walk test was higher (more
severe) in COPD (Table 6).
A scatter plot of dyspnoea and O2 saturation at the end of
the exercise test was shown in Fig. 1.
Discussion
In the present study, we compared dyspnoea and desatura-
tion between IPF and COPD during a 6-min walk test, the
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Table 4 Correlation between dyspnoea at end of 6-min
walk test and various physiologic parameters.
Variables Borg scale at end of 6-min
walk test
IPF COPD
VC –0.35z –0.29
TLC –0.27 –0.06
FEV1 –0.33
z –0.41z
RV/TLC 0.18 –0.33z
IC –0.20 0.24
DLco –0.30 –0.13
PaO2 at rest 0.40z 0.31
O2 saturation at end of
6-min walk test
–0.52y –0.10
Data presented as r values with single regression analysis by
Pearson’s correlation coefficients. yPo0.001; zPo0.01;
zPo0.05.
Table 6 Comparison of 6-min walk distance, O2
saturation, and dyspnoea scale at end of 6-min walk test.
IPF COPD P-value
Six-min walk
distance (m)
5197105 4767120 NS
O2 saturation at
end of 6-min walk
test (%)
83.679.1 88.075.9 o0.001
Borg scale 3.672.1 4.671.9 o0.05
Data presented as mean7SD.
Table 3 Results of stepwise multiple regression analy-
sis.
Variables Six-min walk distance (m)
IPF COPD
VC 0.22 —
TLC 0.17 —
FEV1 — 0.29
RV/TLC — 0.22
IC — —
DLco 0.08 —
PaO2 at rest — —
O2 saturation at end of
6-min walk test
— —
Cumulative r2 0.47 0.51
Data presented as r2 values with stepwise multiple regression
analysis. All values listed represent statistically significant
relationships. Missing values indicate no significant relation-
ships.
Table 5 Results of stepwise multiple regression analy-
sis.
Variables Borg scale at end of 6-min
walk test
IPF COPD
VC — —
TLC — —
FEV1 — 0.16
RV/TLC — —
IC — —
DLco — —
PaO2 at rest — —
O2 saturation at end of
6-min walk test
0.27 —
Cumulative r2 0.27 0.16
Data presented as r2 values with stepwise multiple regression
analysis. All values listed represent statistically significant
relationships. Missing values indicate no significant relation-
ships.
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Figure 1 A scatter plot of O2 saturation and dyspnoea at end
of 6-min walk test in patients with idiopathic pulmonary
fibrosis. Black and white circles show O2 saturation and
dyspnoea, respectively, assessed by modified Borg scale at end
of the 6-min walk test. Some circles are piled up on same
points. Bars beside circles show 95% confidence intervals.
O. Nishiyama et al.836most prevalent method to evaluate exercise capacity in
chronic respiratory disorder. We chose COPD for the
comparison because it is the most studied chronic lung
disease to date, and the results of the study can lead to
further progress in the evaluation and treatment in IPF. Ours
is the first report in English that demonstrated the
differences between IPF and COPD. Among correlates of
the 6-min walk distance, VC, TLC, and DLco were found to
be the most significant predictors of the 6-min walk distance
in IPF, whereas FEV1 and RV/TLC were the predictors in
COPD. It seems only natural that VC, TLC, and DLco, which
are indices of restrictive lung disease, were the most
significant correlates of the 6-min walk distances in IPF
and FEV1 and RV/TLC, just as the indices of obstructive lung
disease, were in COPD. However, for dyspnoea assessed by
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Dyspnoea at 6-min walk test in IPF 837the Borg scale at the end of the 6-min walk test, minimal O2
saturation was the most significant predictor of dyspnoea.
This is a different result from that of the walking distance,
although the same variable, FEV1, was revealed to be a
significant predictor of both 6-min walk distance and
dyspnoea in COPD. Thus, our study demonstrated that
desaturation is important for dyspnoea during functional
exercise in IPF, which is quite different from the fact that an
obstructive disorder resulting in dynamic hyperinflation of
the lungs during exercise contributes to dyspnoea in COPD.
This is a striking difference between IPF and COPD.
A comparison between IPF and COPD regarding the
dyspnoea and O2 saturation at the end of the 6-min walk
test revealed that dyspnoea was more severe in COPD as
desaturation was in IPF, although the 6-min walk distance
was comparable in the two. The reason for the phenomenon
observed in the present study of the milder dyspnoea
despite the more severe desaturation in IPF remains
unknown. One possible reason is dynamic hyperinflation of
the lungs, one of the most important characteristics of
COPD.20–22 Although desaturation is one of the factors that
cause dyspnoea during exercise in patients with a respira-
tory disorder, the mechanisms of dyspnoea are considered to
be multi-factorial.23 In COPD, this dynamic hyperinflation
possibly contributes to exertional dyspnoea much more than
other causative mechanisms such as a decrease in O2
saturation. Lack of this dynamic hyperinflation can explain
the milder dyspnoea at the end of the 6-min walk test in IPF.
However, further examination is needed to elucidate the
difference in the degree of dyspnoea between IPF and
COPD.
The results of the present study may lead to various
interpretations. Desaturation, for example, does not appear
to contribute much to dyspnoea during the walk test in
COPD. In contrast, the contribution of desaturation to
dyspnoea seems to be greater in IPF. Because dyspnoea
assessed with the Baseline Dyspnoea Index,24 which is
considered to be dyspnoea in daily activities, has been
demonstrated to be the factor most correlated with health-
related quality of life in IPF,15 the results of the present
study may suggest the possibility that supplemental O2
alleviates exertional dyspnoea, and then improves health-
related quality of life in patients with IPF. Recently, much
research is being devoted to evaluating the health-related
quality of life in IPF.15,25,26 Given that elucidating and
managing dyspnoea leads to possible quality of life
improvement in these patients, the results of the present
study are especially relevant in terms of revealing the
further clinical direction of the treatment of patients with
IPF.
Exercise tests have also been reported to be important for
predicting survival of patients with IPF.10–12 Lama et al.11
examined the relationship between desaturation during the
6-min walk test and survival in patients with idiopathic
interstitial pneumonias. They demonstrated that desatura-
tion is the only significant prognostic factor in both IPF as
well as non-specific interstitial pneumonia. Hallstrand et
al.12 also reported the importance of the timed walk test in
IPF for its prognostic value demonstrating walk velocity and
change in O2 saturation with the test being a significant
prognostic factor. Although walk distance is usually con-
sidered to reflect exercise capacity and be valuable forpredicting survival in COPD,8 desaturation seems to be more
important when the 6-min walk test is adopted to evaluate
exercise capacity and predict the mortality of patients with
IPF.11,12 Although whether or not O2 supplementation can
improve the survival of patients with IPF is not yet known
and must be examined in further clinical trials, it may well
prolong survival given that exertional desaturation has a
great impact on survival in IPF.
One of the limitations of this study is that only patients
with mild to moderate lung impairment (VC; 76.6716.8%
and PaO2; 82.3714.2mmHg) were included, leaving it
unclear whether these results can be applied to more
severe cases. Further studies comparing more severe cases
with IPF and COPD are needed. Another drawback of the
study is that it may not be appropriate to match age and
PaO2 value when selecting COPD patients as a control, since
any exact comparison of these two different diseases is
admittedly impossible. However, the 6-min walk test is
adopted and studied the most in COPD, and using COPD
patients for the control is one way to better determine the
characteristics of patients with IPF during a 6-min walk test.
Comparison to COPD may also lead to new directions in IPF
research. It might be that a total evaluation of patients with
IPF including not only lung function but also exercise
capacity and dyspnoea could become important in IPF as it
currently is in COPD. Further, the possible efficacy of
treatments already demonstrated to be effective in COPD,
such as long-term oxygen therapy and pulmonary rehabilita-
tion,5 can thus be considered in IPF.
In conclusion, O2 saturation is an independent predictor
of dyspnoea at the end of the 6-min walk test in IPF. In
comparison with COPD, desaturation is more severe in IPF,
although dyspnoea is less so.
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